John Marioni elected to EMBO Membership
Senior Group Leader, Dr John Marioni, has been elected a member of the European Molecular Biology Organisation (EMBO) in recognition of his high-quality life science research.
Marioni is one of 64 life scientists that have been elected to EMBO membership this year, joining a community of more than 1,800 leading life scientists.
EMBO Members are actively involved in the organisation. They serve on EMBO Council, Committees, and Advisory Editorial Boards of EMBO Press journals, evaluate applications for EMBO funding, and mentor early-career scientists. Collectively, they can influence the direction of the life sciences in Europe and beyond.
“I am delighted to welcome the new members into our organisation and look forward to working with them,” says EMBO Director Maria Leptin. “An election to the EMBO Membership recognises outstanding achievements in the life sciences. The new members will provide expertise and guidance that will help EMBO to further strengthen its initiatives.”
New members are nominated and elected by the existing EMBO Membership; it is not possible to apply to become a member. One election is held each year. The new EMBO Members will be formally welcomed at the annual EMBO Members’ Meeting between 27 and 29 October 2021.
Related News
See all news-
Imaging technique allows rapid assessment of ovarian cancer subtypes and their response to treatment
6th December 2024
An MRI-based imaging technique developed at the Institute predicts the response of ovarian cancer tumours to treatment, and rapidly reveals how well treatment is working, in patient-derived cell models.
Find out more -
Isabel Esain Garcia awarded PhD Thesis Prize
3rd December 2024
The Prize is awarded annually to a student who has undertaken an outstanding research project to the highest standards during the course of their PhD study at the Cancer Research UK Cambridge Institute.
Find out more -
World first trial to revolutionise treatment of brain cancer
23rd October 2024
A pioneering research study will trial multiple new treatments for people in the UK living with glioblastoma, an aggressive form of brain cancer.
Find out more